Google-backed Isomorphic Raises $2.1 Billion for Drug Discovery

Isomorphic Labs, a subsidiary of Google, has raised $2.1 billion in funding to scale its AI-powered drug discovery platform. The company plans to use the funds to accelerate the development of new therapeutics and expand its R&D capacity. Operating as an Alphabet subsidiary, Isomorphic applies deep learning models to biological data to identify drug candidates faster and at lower cost. The funding round reflects confidence in the commercial potential of the company's technology. This investment underscores the growing role of artificial intelligence in the healthcare sector. Isomorphic leverages Google's technological infrastructure, particularly in protein structure prediction and molecular simulation. The company aims to use the resources to accelerate its preclinical and clinical-stage projects and forge new partnerships. The investment confirms belief in the transformative impact of AI on the drug discovery process. This is not investment advice.

📊 GOOGL — Piyasa Yorumu

■ neutral · 30%

The news announces Google's major investment in AI-powered drug discovery, but this is not a direct short-term catalyst for GOOGL stock. Technical indicators are weak: the price is below the 20- and 50-day moving averages, the RSI at 42 is near the selling zone, and the MACD is negative below the signal line. Short-term momentum remains bearish, so the positive impact of the news may be limited. Investors should monitor whether the price can hold the $387 support level for a clearer directional signal.

RSI 14

42.1

MACD

-1.87

24h Δ

-2.29%

📊 GOOG — Piyasa Yorumu

■ neutral · 60%

While the news highlights Google's strategic investment in AI-powered drug discovery, it is not a catalyst that will directly impact short-term price movements. Technical indicators present a weak outlook: RSI at 40 is near the sell zone, MACD is below the signal line, and the price is trading below both the 20-day and 50-day moving averages. The 2.5% decline over the past 24 hours confirms the prevailing selling pressure. Although the news is positive, the technical picture does not show sufficient strength for a short-term recovery; therefore, a neutral stance is more appropriate.

RSI 14

40.9

MACD

-1.88

24h Δ

-2.53%

Canlı Grafikler